Cargando…

A Novel PBPK Modeling Approach to Assess Cytochrome P450 Mediated Drug‐Drug Interaction Potential of the Cytotoxic Prodrug Evofosfamide

Evofosfamide is a cytotoxic small‐molecule prodrug preferentially activated under hypoxic conditions. The cytotoxicity of evofosfamide impacted the generation of in vitro drug‐drug interaction (DDI) data, especially in vitro induction results. Therefore, a novel physiologically based pharmacokinetic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lüpfert, Christian, Dyroff, Martin, von Richter, Oliver, Gallemann, Dieter, El Bawab, Samer, Dolgos, Hugues, Jung, Don, Hecht, Stefan, Johne, Andreas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6310869/ https://www.ncbi.nlm.nih.gov/pubmed/30311747 http://dx.doi.org/10.1002/psp4.12360

Ejemplares similares

The hypoxia-activated prodrug evofosfamide in combination with multiple regimens of radiotherapy
por: Nytko, Katarzyna J., et al.
Publicado: (2017)

In vitro and in vivo drug disposition of cilengitide in animals and human
por: Dolgos, Hugues, et al.
Publicado: (2016)

Efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in nasopharyngeal carcinoma in vitro and in vivo
por: Huang, Yan, et al.
Publicado: (2018)

Requirements to Establishing Confidence in Physiologically Based Pharmacokinetic (PBPK) Models and Overcoming Some of the Challenges to Meeting Them
por: Peters, Sheila Annie, et al.
Publicado: (2019)

Hepatic Cytochrome P450 Abundance and Activity in the Developing and Adult Göttingen Minipig: Pivotal Data for PBPK Modeling
por: Buyssens, Laura, et al.
Publicado: (2021)

Anticancer efficacy of the hypoxia‐activated prodrug evofosfamide (TH‐302) in osteolytic breast cancer murine models
por: Liapis, Vasilios, et al.
Publicado: (2016)

Anticancer efficacy of the hypoxia‐activated prodrug evofosfamide is enhanced in combination with proapoptotic receptor agonists against osteosarcoma
por: Liapis, Vasilios, et al.
Publicado: (2017)

Role of cytochrome P450 in drug interactions
por: Bibi, Zakia
Publicado: (2008)

The Effect of 5-Aminolevulinic Acid on Cytochrome P450-Mediated Prodrug Activation
por: Miura, Mai, et al.
Publicado: (2015)

Hypoxia Imaging With PET Correlates With Antitumor Activity of the Hypoxia-Activated Prodrug Evofosfamide (TH-302) in Rodent Glioma Models
por: Stokes, Ashley M., et al.
Publicado: (2016)

Editorial: Precision Medicine: Impact of Cytochromes P450 and Transporters Genetic Polymorphisms, Drug-Drug Interactions, Disease on Safety and Efficacy of Drugs
por: Daali, Youssef, et al.
Publicado: (2022)

Effects of Tenapanor on Cytochrome P450‐Mediated Drug‐Drug Interactions
por: Johansson, Susanne, et al.
Publicado: (2017)

Retraction: Role of cytochrome P450 in drug interactions
por: Bibi, Zakia
Publicado: (2014)

Cytochrome P450 Enzymes and Drug Metabolism in Humans
por: Zhao, Mingzhe, et al.
Publicado: (2021)

An Intratumor Pharmacokinetic/Pharmacodynamic Model for the Hypoxia-Activated Prodrug Evofosfamide (TH-302): Monotherapy Activity is Not Dependent on a Bystander Effect()()
por: Hong, Cho Rong, et al.
Publicado: (2018)

Hypoxia-Targeting Drug Evofosfamide (TH-302) Enhances Sunitinib Activity in Neuroblastoma Xenograft Models()
por: Kumar, Sushil, et al.
Publicado: (2018)

Cytochrome P450-Based Drug-Drug Interactions of Vonoprazan In Vitro and In Vivo
por: Wang, Yiran, et al.
Publicado: (2020)

In Silico Prediction of Drug–Drug Interactions Mediated by Cytochrome P450 Isoforms
por: Dmitriev, Alexander V., et al.
Publicado: (2021)

A Combination of Radiation and the Hypoxia-Activated Prodrug Evofosfamide (TH-302) is Efficacious against a Human Orthotopic Pancreatic Tumor Model()()
por: Hajj, Carla, et al.
Publicado: (2017)

Use of Drugs that Act on the Cytochrome P450 System in the Elderly
por: Cabrera, Marcos A S, et al.
Publicado: (2009)

Clinical Pharmacogenetics of Cytochrome P450-Associated Drugs in Children
por: Aka, Ida, et al.
Publicado: (2017)

PBPK modeling and simulation in drug research and development
por: Zhuang, Xiaomei, et al.
Publicado: (2016)

Drug-drug interaction of acetaminophen and roxithromycin with the cocktail of cytochrome P450 and hepatotoxicity in rats
por: Liu, Xiang, et al.
Publicado: (2020)

A phase 1 ‘window-of-opportunity’ trial testing evofosfamide (TH-302), a tumour-selective hypoxia-activated cytotoxic prodrug, with preoperative chemoradiotherapy in oesophageal adenocarcinoma patients
por: Larue, Ruben T. H. M., et al.
Publicado: (2016)

Comparative Cytochrome P450 In Vitro Inhibition by Atypical Antipsychotic Drugs
por: Gervasini, Guillermo, et al.
Publicado: (2013)

An update on the role of intestinal cytochrome P450 enzymes in drug disposition
por: Xie, Fang, et al.
Publicado: (2016)

Effect of health foods on cytochrome P450-mediated drug metabolism
por: Sasaki, Takamitsu, et al.
Publicado: (2017)

A history of the roles of cytochrome P450 enzymes in the toxicity of drugs
por: Guengerich, F. Peter
Publicado: (2020)

Inflammatory signaling on cytochrome P450-mediated drug metabolism in hepatocytes
por: Wang, Xiaokang, et al.
Publicado: (2022)

Reviewing Data Integrated for PBPK Model Development to Predict Metabolic Drug-Drug Interactions: Shifting Perspectives and Emerging Trends
por: Abouir, Kenza, et al.
Publicado: (2021)

African Genetic Diversity: Implications for Cytochrome P450-mediated Drug Metabolism and Drug Development
por: Rajman, Iris, et al.
Publicado: (2017)

Interaction of proton pump inhibitors with cytochromes P450: consequences for drug interactions.
por: Meyer, U. A.
Publicado: (1996)

Prediction of cytochrome P450 isoform responsible for metabolizing a drug molecule
por: Mishra, Nitish K, et al.
Publicado: (2010)

Role of cytochrome P450 genotype in the steps toward personalized drug therapy
por: Cavallari, Larisa H, et al.
Publicado: (2011)

Cytochrome P450 enzyme mediated herbal drug interactions (Part 1)
por: Wanwimolruk, Sompon, et al.
Publicado: (2014)

Cytochrome P450 enzyme mediated herbal drug interactions (Part 2)
por: Wanwimolruk, Sompon, et al.
Publicado: (2014)

Structure-Based Drug Design for Cytochrome P450 Family 1 Inhibitors
por: Dutkiewicz, Zbigniew, et al.
Publicado: (2018)

Computational methods and tools to predict cytochrome P450 metabolism for drug discovery
por: Tyzack, Jonathan D., et al.
Publicado: (2019)

Hydroxylation of Antitubercular Drug Candidate, SQ109, by Mycobacterial Cytochrome P450
por: Bukhdruker, Sergey, et al.
Publicado: (2020)

Inhibition of Cytochrome P450 Enzymes by Drugs—Molecular Basis and Practical Applications
por: Guengerich, F. Peter
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_r06e1t4ud2nihtsui9sg1shg39